Mersana Therapeutics
在场
高管
查看带有其 19 名主要高管的组织结构图
Mersana Therapeutics 搜索最多的简介
- Martin Huber, Director, President and Chief Executive Officer
- Anna Protopapas, Director
- Kristen Hege, Director
高管在Mersana Therapeutics变化
- Martin Huber 曾任 Director, 现升职为 Director, President and Chief Executive Officer (新闻发布的2023九月7号).
- Brian DeSchuytner 曾任 Senior Vice President and Chief Financial Officer, 现升职为 Senior Vice President, Chief Operating Officer and Chief Financial Officer (新闻发布的2023九月7号).
- Mohan Bala 曾任 Senior Vice President, Strategic Product Planning & Program Leadership, 现升职为 Senior Vice President and Chief Development Officer (新闻发布的2023九月7号).
创建提醒
跟踪 Mersana Therapeutics 的高管变动
生物技术
Mersana Therapeutics 拥有 2,290 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Delphia Therapeutics 刚刚宣布为 67 筹款数百万美元。 (公布2024五月7号).
- Karius 刚刚宣布为 100 筹款数百万美元。 (公布2024五月3号).
- Transcarent 刚刚宣布为 126 筹款数百万美元。 (公布2024五月2号).
生物技术 行业的其他推荐联系人
消息
Mersana Therapeutics 的最新新闻稿
- Press Releases - Mersana Therapeutics
- Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting - Mersana Therapeutics
- Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study - Mersana Therapeutics
- Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress - Mersana Therapeutics
- Mersana Therapeutics to Present at Upcoming Investor Conferences - Mersana Therapeutics
- Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mersana Therapeutics
- Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs - Mersana Therapeutics
- Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer - Mersana Therapeutics
- Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update - Mersana Therapeutics
- Mersana Therapeutics to Present at Upcoming Investor Conferences - Mersana Therapeutics
- View more press releases Close
通过电子邮件
